The U.S. Food and Drug Administration (FDA) approved Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age.
The approval of viloxazine is supported by data from an extensive development program consisting of four Phase III clinical trials that studied more than 1000 pediatric patients from the age of 6 to 17 years.
>> Supernus Pharmaceuticals Press Release
Reference:
Yu C et al. J Exp Pharmacol. 2020 Aug 25;12:285-300. Abstract
For more information: